1[1]Pfeifer M A,Schumer M P,Gelber D A.Aldose reductase inhibitors:the end of an era or the need for different trial designs[J].Diabetes,1997,46(2):s82.
2[2]Britaland S T,Young R J,Sharma A X,et al.Relationship of endoneurial capillary abnormalities to type and senerity of diabetic polyneuropatby[J].Diabetes,1990,39:909.
2Cameron NE, Eaton SE, Cotter MA, et al. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001;44∶1973-1988.
3Cameron NE, Cotter MA. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes 1997;46(2)∶31-37.
4Veves A, Akbari CM, Primauexa J, et al. Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes, 1998;47(3)∶457-463.
5Vinik A. Diabetic neuropathy: pathogenesis and therapy. Am J Med 1999; 107(2)∶17-26.
6Nakamura J, Kato K Hamada Y, et al. A protein kinase C-beta-selective inhibitor ameliorates neural dysfuction in STZ-induced diabetic rats. Diabetes 1999;48∶2090.
7Shii DN. Implication of insulin growth factors in the pathogenesis of diabetic neuropathy. Brain Res Revi 1995;20∶47-67.
8Higeta H, Yamaguchi M, Nakano Y, et al. Serum autoantibodies against sulfatides and phospholipid in NIDDM patients with diabetic neuropathy. Diabetes Care 1997;20(12)∶1896-1899.
9Ilicevic Z, Liuzzi FJ, Pittenger GL, et al. Morphometric and immunopathologic characteristics of sural nerve from patients with distal symmetric diabetic neuropathy. Diabetes 1998;47(1)∶43-49.
